Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Assets for 10 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 1.93% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, up 1.93% year-over-year, with the annual reading at $1.5 billion for FY2025, 1.93% up from the prior year.
  • Assets for Q4 2025 was $1.5 billion at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • The five-year high for Assets was $1.6 billion in Q3 2022, with the low at $1.2 billion in Q3 2025.
  • Average Assets over 5 years is $1.4 billion, with a median of $1.5 billion recorded in 2021.
  • The sharpest move saw Assets increased 29.57% in 2021, then decreased 23.5% in 2023.
  • Over 5 years, Assets stood at $1.5 billion in 2021, then increased by 1.51% to $1.5 billion in 2022, then decreased by 3.52% to $1.5 billion in 2023, then increased by 0.8% to $1.5 billion in 2024, then increased by 1.93% to $1.5 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $1.5 billion, $1.2 billion, and $1.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.